CAM
MRVI icon

Claret Asset Management’s Maravai LifeSciences MRVI Stock Holding History

Claret Asset Management’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-25,181
Closed -$180K – 346
2024
Q2 		$180K Buy
25,181
+14,233
+130% +$123K 0.03% 244
2024
Q1 		$95K Sell
10,948
-862
-7% -$5.83K 0.02% 207
2023
Q4 		$77K Buy
11,810
+132
+1% +$853 0.01% 189
2023
Q3 		$117K Hold
11,678
– – 0.02% 149
2023
Q2 		$145K Buy
+11,678
New +$158K 0.03% 149

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Claret Asset Management's MRVI Position: Q3 2024 in Review

Claret Asset Management sold out of Maravai LifeSciences (MRVI) in Q3 2024, closing a stake of 25,181 shares — an estimated $180K sold.

Claret Asset Management first reported a position in MRVI in Q2 2023 and held it in 5 quarters. The position peaked at $180K in Q2 2024. 217 funds tracked by Wall St. Rank hold MRVI as of Q3 2024.

  • Claret Asset Management reported no remaining Maravai LifeSciences position as of Q3 2024 after selling out during the quarter.
  • Claret Asset Management sold 25,181 Maravai LifeSciences shares in Q3 2024, an estimated $180K.
  • Claret Asset Management first reported a position in Maravai LifeSciences in Q2 2023 and held it in 5 quarters.
  • Claret Asset Management's Maravai LifeSciences position peaked at $180K in Q2 2024.
  • 217 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2024.

Based on Claret Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.